Compare Amphastar Pharmaceuticals Inc (AMPH) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Caesars Entertainment Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Caesars Entertainment Inc trades at $29.86 (market cap $6.08B). The key difference: Caesars Entertainment Inc is far larger — about 7.4× Amphastar Pharmaceuticals Inc's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | CZR | |
|---|---|---|
Market Cap | $826.08M | $6.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $30.84 |
52-Week Low | $16.87 | $18.14 |
Enterprise Value | $1.22B | $30.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CZR trades at $29.84, up 0.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $31.27. The company reported Q1 2026 EPS of -$0.48, missing expectations, and has a negative net income margin of -4.19%. Recent news highlights the pending acquisition by Fertitta Entertainment and the opening of Caesars Republic Lake Tahoe.
CZR faces headwinds from recent earnings misses and negative profitability, but the acquisition offer and improving cash flow trends provide upside potential. Risks include high debt levels and competitive pressures in the leisure sector. Analyst sentiment is mixed with 33% buy ratings, suggesting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
